Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The addressable obesity patient population conservatively estimated at 800 million people globally with BMI above 30, and considerably more when including the overweight population with comorbidities that justify pharmacotherapy dwarfs the T2DM market
Though the trial was powered to only detect non-inferiority, the observed (non-significant) hazard ratio for semaglutide vs
Semaglutide, originally developed for type 2 diabetes, has demonstrated cardiovascular benefits in large clinical trials, including meaningful reductions in blood pressure among overweight and obese patients
In addition, the initiation of L-dopa therapy in PD patients causes the development of hyperhomocysteinemia, which may help to explain why neuropsychiatric diseases continue to spread in PD patients
US$ 26.31
US$ 22.58
US$ 25.29
US$ 24.18
US$ 25.58
US$ 24.40
US$ 28.66
US$ 22.94
US$ 22.82
